Abstract
The prospects for effectively treating well-established dementia, such as Alzheimer’s disease (AD), are slim, due to the destruction of key brain pathways that underlie higher cognitive function. There has been a substantial shift in the field towards detecting conditions such as AD in their earliest stages, which would allow preventative or therapeutic approaches to substantially reduce risk and/or slow the progression of disease. AD is characterized by hallmark pathological changes such as extracellular Aβ plaques and intracellular neurofibrillary pathology, which selectively affect specific subclasses of neurons and brain circuits. Current evidence indicates that Aβ plaques begin to form many years before overt dementia, a gradual and progressive pathology which offers a potential target for early intervention. Early Aβ changes in the brain result in localized damage to dendrites, axonal processes and synapses, to which excitatory synapses and the processes of projection neurons are highly vulnerable. Aβ pathology is replicated in a range of transgenic models overexpressing mutant human familial AD genes (eg APP and presenilin 1). Studying the development of aberrant regenerative and degenerative changes in neuritic processes associated with Aβ plaques may represent the best opportunity to understand the relationship between the pathological hallmarks of AD and neuronal damage, and to develop early interventions to prevent, slow down or mitigate against Aβ pathology and/or the neuronal alterations that leads to cognitive impairment.
Keywords: Alzheimer’s disease, amyloid precursor protein, Aß, plaque, dystrophic neurite, selective vulnerability, transgenic mice.
Current Alzheimer Research
Title:Defining the earliest pathological changes of Alzheimer’s disease
Volume: 13 Issue: 3
Author(s): James C. Vickers, Stan Mitew, Adele Woodhouse, Carmen M. Fernandez-Martos, Mathew T. Kirkcaldie, Alison J. Canty, Graeme H. McCormack and Anna E. King
Affiliation:
Keywords: Alzheimer’s disease, amyloid precursor protein, Aß, plaque, dystrophic neurite, selective vulnerability, transgenic mice.
Abstract: The prospects for effectively treating well-established dementia, such as Alzheimer’s disease (AD), are slim, due to the destruction of key brain pathways that underlie higher cognitive function. There has been a substantial shift in the field towards detecting conditions such as AD in their earliest stages, which would allow preventative or therapeutic approaches to substantially reduce risk and/or slow the progression of disease. AD is characterized by hallmark pathological changes such as extracellular Aβ plaques and intracellular neurofibrillary pathology, which selectively affect specific subclasses of neurons and brain circuits. Current evidence indicates that Aβ plaques begin to form many years before overt dementia, a gradual and progressive pathology which offers a potential target for early intervention. Early Aβ changes in the brain result in localized damage to dendrites, axonal processes and synapses, to which excitatory synapses and the processes of projection neurons are highly vulnerable. Aβ pathology is replicated in a range of transgenic models overexpressing mutant human familial AD genes (eg APP and presenilin 1). Studying the development of aberrant regenerative and degenerative changes in neuritic processes associated with Aβ plaques may represent the best opportunity to understand the relationship between the pathological hallmarks of AD and neuronal damage, and to develop early interventions to prevent, slow down or mitigate against Aβ pathology and/or the neuronal alterations that leads to cognitive impairment.
Export Options
About this article
Cite this article as:
Vickers C. James, Mitew Stan, Woodhouse Adele, Fernandez-Martos M. Carmen, Kirkcaldie T. Mathew, Canty J. Alison, McCormack H. Graeme and King E. Anna, Defining the earliest pathological changes of Alzheimer’s disease , Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151218150322
DOI https://dx.doi.org/10.2174/1567205013666151218150322 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Contribution of Oxazolidinone Frame to The Biological Activity of Pharmaceutical Drugs and Natural Products
Mini-Reviews in Medicinal Chemistry Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
Current Neuropharmacology Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Difficulties in the Management of Frontal Dementia: Therapeutics Strategies
Letters in Drug Design & Discovery What is Tobacco Smoke? Sociocultural Dimensions of the Association with Cardiovascular Risk
Current Pharmaceutical Design Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Statins, Risk of Death and Ischemic Stroke in Patients with Dementia: A Registry-Based Observational Cohort Study
Current Alzheimer Research Systemic Administration of Fluoro-Gold for the Histological Assessment of Vascular Structure, Integrity and Damage
Current Neurovascular Research Progressive Supranuclear Palsy: What Do We Know About it?
Current Medicinal Chemistry High Doses of In vitro Beta-carotene, Alpha-Tocopherol and Ascorbic Acid Induce Oxidative Stress and Secretion of IL-6 in Peripheral Blood Mononuclear Cells from Healthy Donors
Current Aging Science Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Bioactive Fish Fatty Acids: Health Effects and Their Use as Functional Food Ingredients
Current Nutrition & Food Science ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease
Current Drug Targets Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Clearance of Amyloid-β Peptide by Neuronal and Non-Neuronal Cells: Proteolytic Degradation by Secreted and Membrane associated Proteases
Current Neurovascular Research Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry